Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of Elafin Immunohistochemical Expression as Marker of Cervical Cancer Severity

Full text
Longatto-Filho, Adhemar [1, 2, 3] ; Fregnani, Jose Humberto [4] ; da Costa, Allini Mafra [1, 5] ; de Araujo-Souza, Patricia Savio [6] ; Scapulatempo-Neto, Cristovam [1, 7] ; Herbster, Suellen [8] ; Boccardo, Enrique [8] ; Termini, Lara [9]
Total Authors: 8
[1] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos - Brazil
[2] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM 14, Sao Paulo, SP - Brazil
[3] Univ Minho, ICVS 3Bs, Life & Hlth Sci Res Inst, Sch Med, Braga - Portugal
[4] AC Camargo Canc Ctr, Sao Paulo, SP - Brazil
[5] Int Agcy Res Canc, Canc Surveillance Sect, Lyon - France
[6] Univ Fed Parana, Dept Genet, Lab Immunogenet & Histocompatibil, Curitiba, Parana - Brazil
[7] DASA Labs, Pathol & Mol Diagnost GeneOne, Sao Paulo, SP - Brazil
[8] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, SP - Brazil
[9] Univ Sao Paulo, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP - Brazil
Total Affiliations: 9
Document type: Journal article
Web of Science Citations: 0

Introduction: The main risk factor for the development of cervical cancer (CC) is persistent infection by human papillomavirus (HPV) oncogenic types. In order to persist, HPV exhibits a plethora of immune evasion mechanisms. PI3/Elafin (Peptidase Inhibitor 3) is an endogenous serine protease inhibitor involved in epithelial protection against pathogens. PI3/Elafin's role in CC is still poorly understood. Materials and Methods: In the present study, we addressed PI3/Elafin protein detection in 123 CC samples by immunohistochemistry and mRNA expression in several datasets available at Gene Expression Omnibus and The Cancer Genome Atlas platforms. Results: We observed that PI3/Elafin is consistently downregulated in CC samples when compared to normal tissue. Most of PI3/Elafin-positive samples exhibited this protein at the plasma membrane. Besides, high PI3/Elafin expression at the cellular membrane was more frequent in in situ stages I + II than in invasive cervical tumor stages III + IV. This indicates that PI3/Elafin expression is gradually lost during the CC progression. Of note, advanced stages of CC were more frequently associated with a more intense PI3/Elafin reaction in the nuclei and cytoplasm. Conclusion: Our results suggest that PI3/Elafin levels and subcellular localization may be used as a biomarker for CC severity. (AU)

FAPESP's process: 08/57889-1 - Institute of Science and Technology to study Diseases Associated with Papillomavirus
Grantee:Luisa Lina Villa
Support type: Research Projects - Thematic Grants
FAPESP's process: 18/22097-0 - Malignant neoplasms of the 18 cities of Barretos Regional Health District (RhD), Sao Paulo, Brazil: the importance of a population-based cancer registry
Grantee:Allini Mafra da Costa
Support type: Scholarships in Brazil - Post-Doctorate